Pipeline of GVHD Market (Graft Versus Host Disease) H1 2016

Press Release

Graft Versus Host Disease (GVHD) Pipeline Market Companies Involved in Therapeutics Development are AbbVie Inc., AbGenomics International, Inc., Actelion Ltd, Alexion Pharmaceuticals, Inc., Apceth GmbH & Co. KG, arGEN-X BV, Athersys, Inc., Bellicum Pharmaceuticals, Inc., Bio-Cancer Treatment International Limited, Biogen, Inc., Bristol-Myers Squibb Company, Caladrius Biosciences, Inc., Cantex Pharmaceuticals, Inc., Cell2B S.A., CellECT Bio, Inc., Cynata Therapeutics Limited, Cytodyn Inc., Dr. Falk Pharma GmbH, Effimune SAS, Escape Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Fate Therapeutics, Inc., Generon (Shanghai) Corporation Ltd., GlaxoSmithKline Plc, Idera Pharmaceuticals, Inc., ImmuNext, Inc., Immunomedics, Inc., Incyte Corporation, Kadmon Corporation, LLC, Kamada Ltd., Kiadis Pharma B.V., Kymab Limited, Kyorin Pharmaceutical Co., Ltd., MacroGenics, Inc., Mallinckrodt Plc, Medsenic, Mesoblast Limited, Millennium Pharmaceuticals, Inc., Neopharm Ltd., Novartis AG, OncoImmune, Inc., Pharmicell Co., Ltd., REGiMMUNE Corporation, Rigel Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Seattle Genetics, Inc., Seres Therapeutics, Inc., Sigmoid Pharma Limited, Spherium Biomed S.L., Targazyme, Inc., Therapix Biosciences Ltd, Tobira Therapeutics, Inc., Xenikos B.V. and ZIOPHARM Oncology, Inc.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Get discount on this research report at http://www.rnrmarketresearch.com/contacts/discount?rname=539818

The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects.

Scope

– The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD)

– The report reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Graft Versus Host Disease (GVHD) therapeutics and enlists all their major and minor projects

– The report assesses Graft Versus Host Disease (GVHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD)

Complete research report of 367 pages with TOC is available at http://www.rnrmarketresearch.com/graft-versus-host-disease-gvhd-pipeline-review-h1-2016-market-report.html

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD)

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline